Immunotherapy may be an effective treatment for some gliomas

Written by Naomi Baba, Future Science Group

A recent study involving 25 international institutions, led by researchers from Columbia University Vagelos College of Physicians and Surgeons (NY, USA) and published in Nature Medicine, has revealed that gliomas in neurofibromatosis type 1 (NF1) patients may be effectively treated by immunotherapy. NF1 can cause slow-growing gliomas in children and aggressive forms of the tumor in adults, both of which are challenging to treat with conventional means. The research team, led by Antonio Iavorone and Anna Lasorella (both Columbia University), analyzed tumor samples from 56 participants to create a comprehensive landscape of genetic, epigenetic and immune alterations in NF1 glioma...

To view this content, please register now for access

It's completely free